ProQR Therapeutics N.V. (PRQR) | Investment Case

1. Company Snapshot

1.a. Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.The company also engages in the developing of Axiomer RNA base-editing platform technology.

It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Show Full description

1.b. Last Insights on PRQR

ProQR Therapeutics N.V.'s recent performance was negatively impacted by its Q4 loss of $0.10 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07. This earnings miss, coupled with a year-over-year increase in loss from $0.08 per share, suggests a slowdown in the company's financial performance. Additionally, the company's financial and operating results for the year ended December 31, 2024, showed a decline in revenue, further exacerbating the negative trend.

1.c. Company Highlights

Last Price	2.09
Change Percentage	-1.42%
Open	2.11
Previous Close	2.12
Market Cap ( Millions)	220
Volume	681558
Year High	3.71
Year Low	1.07
M A 50	2.37
M A 200	2.02

FCF Yield	-22.72%
Dividend Yield	0.00%
ROE	-61.16%
Debt / Equity	25.17%
Net Debt / EBIDTA	288.25%
Price To Book	2.82
Price Earnings Ratio	-4.77
Price To FCF	-4.4
Price To sales	11.47
EV / EBITDA	-2.41

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Dec -01

Source: globenewswire.com

ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates

Nov -06

Source: zacks.com

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov -06

Source: globenewswire.com

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Nov -03

Source: seekingalpha.com

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct -20

Source: globenewswire.com

ProQR to Participate in Upcoming Investor Conferences in October 2025

Oct -13

Source: globenewswire.com

ProQR to Participate in Upcoming Investor Conferences in October 2025

Oct -13

Source: globenewswire.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

Aug -07

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.43%)

6. Segments

RNA Based Therapeutics

Expected Growth: 11.43%

ProQR Therapeutics N.V.'s RNA-based therapeutics growth is driven by increasing adoption in rare genetic diseases, advancements in RNA editing technologies, and a strong pipeline of candidates. The company's focus on unmet medical needs, strategic partnerships, and expanding research collaborations also contribute to its 11.43% growth.

7. Detailed Products

Sepofarsen

An RNA-based oligonucleotide in development for the treatment of Leber Congenital Amaurosis 10 (LCA10), a severe inherited retinal disease.

QR-421a

An RNA-based oligonucleotide in development for the treatment of Usher syndrome type 2, a genetic disorder that causes hearing loss and vision loss.

QR-1123

An RNA-based oligonucleotide in development for the treatment of Autosomal Dominant Retinitis Pigmentosa (adRP), a genetic disorder that causes vision loss.

QR-313

An RNA-based oligonucleotide in development for the treatment of Fuchs Endothelial Corneal Dystrophy, a genetic disorder that causes vision loss.

8. ProQR Therapeutics N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

ProQR Therapeutics N.V. is a biotech company that focuses on developing RNA-based therapies for severe genetic diseases. The threat of substitutes is medium because while there are other companies working on similar treatments, ProQR's RNA-based approach is unique and has shown promising results.

Bargaining Power Of Customers

ProQR Therapeutics N.V. is a biotech company that focuses on developing RNA-based therapies for severe genetic diseases. The bargaining power of customers is low because the company is still in the development stage and has not yet commercialized any products, giving customers limited bargaining power.

Bargaining Power Of Suppliers

ProQR Therapeutics N.V. relies on suppliers for raw materials and services necessary for its RNA-based therapies. The bargaining power of suppliers is medium because while there are some specialized suppliers, ProQR has some flexibility in choosing its suppliers.

Threat Of New Entrants

The biotech industry is highly competitive, and new entrants can easily disrupt the market. The threat of new entrants is high because ProQR Therapeutics N.V. operates in a highly competitive market with many established players and new entrants.

Intensity Of Rivalry

The biotech industry is highly competitive, and ProQR Therapeutics N.V. operates in a crowded market with many established players. The intensity of rivalry is high because companies are constantly competing for funding, talent, and market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	12.49%
Debt Cost	5.42%
Equity Weight	87.51%
Equity Cost	5.42%
WACC	5.42%
Leverage	14.27%

11. Quality Control: ProQR Therapeutics N.V. passed 4 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

ProQR Therapeutics

A-Score: 4.2/10

Value: 6.4

Growth: 6.6

Quality: 4.1

Yield: 0.0

Momentum: 7.5

Volatility: 0.3

1-Year Total Return ->

Atai Life Sciences

A-Score: 4.0/10

Value: 6.0

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Pharma Mar

A-Score: 3.6/10

Value: 1.1

Growth: 4.4

Quality: 7.8

Yield: 1.2

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

LAVA Therapeutics

A-Score: 3.3/10

Value: 6.8

Growth: 5.6

Quality: 3.0

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

NewAmsterdam Pharma

A-Score: 3.2/10

Value: 6.2

Growth: 4.0

Quality: 4.3

Yield: 0.0

Momentum: 4.5

Volatility: 0.3

1-Year Total Return ->

Calliditas Therapeutics

A-Score: 3.0/10

Value: 6.0

Growth: 4.2

Quality: 3.8

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

13.52%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.42%

ProQR Therapeutics N.V. - NL0010872495

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on PRQR

1.c. Company Highlights

More Volatile

Stable Momentum

Average Quality

Earnings Beats

Revenues Beats

Average Yield

Fairly Valued

Revenues Miss

Strong Momentum

Cheaper

Weak Momentum

Earnings Miss

Average Growth

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.43%)

6. Segments

RNA Based Therapeutics

Expected Growth: 11.43%

7. Detailed Products

Sepofarsen

QR-421a

QR-1123

QR-313

8. ProQR Therapeutics N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: ProQR Therapeutics N.V. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.09$

Current Price

2.09$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA